Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Trading 04-16 15:36:04 EDT

33.64

-0.23

-0.68%

High33.97	Low33.29	Vol567.31K
Open33.82	D1 Closing33.87	Amplitude2.02%
Mkt Cap2.59B	Tradable Cap2.38B	Total Shares76.91M
T/O19.06M	T/O Rate0.80%	Tradable Shares70.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":33.64,"timestamp":1776368159265,"preClose":33.87,"halted":0,"volume":567306,"delay":0,"changeRate":-0.006790670209624945,"floatShares":70781700,"shares":76911300,"eps":-3.9,"marketStatus":"Trading","change":-0.23,"latestTime":"04-16 15:36:04 EDT","open":33.82,"high":33.97,"low":33.285,"amount":19063354.844412,"amplitude":0.020224,"askPrice":33.67,"askSize":101,"bidPrice":33.63,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-3.9,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776369600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":33.87,"preHourTrading":{"tag":"盘前","latestPrice":33.85,"preClose":33.87,"latestTime":"09:25 EDT","volume":7986,"amount":269414.01894000004,"timestamp":1776345900074,"change":-0.02,"changeRate":-0.00059,"amplitude":0.097727},"postHourTrading":{"tag":"盘后","latestPrice":33.87,"preClose":33.87,"latestTime":"17:27 EDT","volume":22310,"amount":755669.1,"timestamp":1776288450239,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.750075,"impliedVol":0.3054,"impliedVolPercentile":0.084},"requestUrl":"/m/hq/s/CLDX/tweets","defaultTab":"tweets","newsList":[{"id":"2627631234","title":"Celldex to join H.C. Wainwright inflammatory skin disease conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2627631234","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627631234?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:02","pubTimestamp":1776110551,"startTime":"0","endTime":"0","summary":"Celldex management will join a fireside chat at H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14 at 3:30 p.m. ET.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL1CyxYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","SG9999014039.USD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014013.SGD","NDAQ","LU2210150020.SGD","CLDX","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014021.USD","BK4139","IE00BN0W2V16.EUR","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625994802","title":"A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2625994802","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625994802?lang=en_us&edition=fundamental","pubTime":"2026-04-08 10:16","pubTimestamp":1775614584,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) recently closed a large underwritten public equity offering, raising about US$345 million soon after sharing new Phase 2 barzolvolimab data in multiple chronic urticaria indications at a major dermatology conference.\nSee our latest analysis for Celldex Therapeutics.\nAt a share price of US$31.35, Celldex has logged a 1 month share price return of 6.52% and a year to date share price return of 16.07%. The 1 year total shareholder return of 107.20% contrasts with a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/a-look-at-celldex-therapeutics-cldx-valuation-after-equity-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/a-look-at-celldex-therapeutics-cldx-valuation-after-equity-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4215","CLDX","BK4139","DCF","EQR","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625604677","title":"Celldex closes common stock offering, raises about $345 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2625604677","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625604677?lang=en_us&edition=fundamental","pubTime":"2026-04-06 22:54","pubTimestamp":1775487246,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics closed an underwritten public offering of 11,896,750 common shares at USD 29 per share.Underwriters exercised option in full to buy 1,551,750 additional shares.Gross proceeds totaled about USD 345 million, excluding underwriting discounts, commissions, and offering expenses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL5DhyTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","SG9999014013.SGD","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","NDAQ","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625641077","title":"Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625641077","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625641077?lang=en_us&edition=fundamental","pubTime":"2026-04-05 20:14","pubTimestamp":1775391243,"startTime":"0","endTime":"0","summary":"In early April 2026, Celldex Therapeutics completed a follow-on public equity offering of 10,345,000 common shares at US$29.00 each, raising about US$300.01 million to support barzolvolimab launch preparation, pipeline development and general corporate needs.\nThis financing closely followed detailed Phase 2 data showing barzolvolimab’s potential to meaningfully improve quality of life in difficult-to-treat chronic urticaria, underscoring Celldex’s focus on translating clinical momentum into...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/did-celldexs-cldx-us300-million-equity-raise-to-fund-barzolv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/did-celldexs-cldx-us300-million-equity-raise-to-fund-barzolv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4215","CHAT","AGIX","AIPO","EQR","BK4528","CLDX","AI","BK4139","BK4551","ARTY","BK4585","BK4588","BK4587","BK4543","BK4023","AIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624797687","title":"Celldex Therapeutics Inc - Offers 10,345,000 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624797687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624797687?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:17","pubTimestamp":1775164622,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L133:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501794","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501794","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624501794?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:10","pubTimestamp":1775135417,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 1.6%, and the actively traded Invesco QQQ Trust (QQQ) was 2.1% lower in Thursday's premarket activity as renewed escalation ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"bc816866c81df567fcf21dbdfc51f412","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IYK","IYW","PMR","XRT","IWM","IVV","XLV","XLE","TTE","XLI","EQR","BITO","IYE","UNG","ESAB","IPK","SPY","RTH.AU","RTH",".DJI","IBB","VHT","APO","VIS","XSD","XLK","VHT.AU","XLP","EETH","IYJ","XLY","FAZ","XLF","EEM","QQQ","VDC","SLV","ORCL","SPY.AU","CLDX","BETH","SOXX","FAS","EXI","IYH","IGM","GLD","USO","IGV","TSLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505605","title":"BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505605?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:36","pubTimestamp":1775129790,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocksWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e5355e74f3a6d8ed27a66eec612a1a71","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL6N40L0UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072463663.USD","LU0648001328.SGD","LU0345770993.USD","IE00BFXG1179.USD","LU1582987597.SGD","LU2087621335.USD","LU2106854487.HKD","LU0788109048.HKD","LU0345781412.USD","BK4558","IE00BK4W5L77.USD","LU0061474705.USD","BK4183","LU1880398471.USD","IE00B3S45H60.SGD","BK7511","LU1366333091.USD","LU2552382215.SGD","IE0034235303.USD","LU1267930813.SGD","LU0788109394.HKD","LU0572108347.SGD","LU0075056555.USD","LU0345780521.USD","LU2237438978.USD","IE00B5949003.HKD","XOM","LU0289941410.SGD","LU0466842654.USD","LU1674673691.USD","LU0138981039.USD","LU2746668461.USD","LU2764263203.CNY","IE00B19Z9Z06.USD","LU0456855351.SGD","HK0000914660.USD","UAL","GSAT","LU0368265418.SGD","LU0175139822.USD","IE00BQJZX424.USD","LU0050427557.USD","WING","LU2360032135.SGD","LU2129689605.HKD","LU2487616109.SGD","IE0009G5SDU7.USD","OXY","IE00BFMHRM44.USD","IE00B19Z8X17.USD","LU0077335932.USD","LU1861558580.USD","LU1496350171.SGD","LU2362541273.HKD","LU1989764664.SGD","SCCO","LU1935042991.SGD","BK7507","LU1366334651.USD","LU1064131342.USD","LU1974910355.USD","LU0820561909.HKD","LU0323591593.USD","LU1894683264.USD","LU0788109477.HKD","LU2065171402.SGD","LU0612318971.USD","IE0004091025.USD","BK7095","LU1935042215.USD","LU0302445910.USD","BK4596","LU1267930573.SGD","BK4535","LU0068578508.USD","LU2023251221.USD","IE0004086264.USD","LU1935043023.USD","SG9999015952.SGD","LU2264538146.SGD","SG9999000418.SGD","LU2054465674.USD","LU0823434740.USD","LU0211331839.USD","LU2065170008.USD","LU0070217475.USD","LU0823421416.USD","AMZP","LU1150488135.SGD","LU1489326972.SGD","LU0898667661.SGD","LU0820562030.AUD","LU0055631609.USD","LU2471134952.CNY","BK4612","LU0971552673.USD","BK4017","LU2125154778.USD","AMZY","LU2552382058.USD","IE00B19Z9505.USD","LU0278409577.USD","IE00BFSS8Q28.SGD","SG9999004303.SGD","LU0109391861.USD","LU0708994859.HKD","LU1791710582.SGD","LU0198837287.USD","LU1629891620.HKD","LU1551013342.USD","XOMZ","LU1069344957.HKD","SG9999014880.SGD","LU0312595415.SGD","AMZU","LU2361044865.SGD","XOMX","LU1261432733.SGD","IE000YTNTUN2.SGD","LU0314104364.USD","LU0368265764.SGD","LU0831103253.SGD","LU2092937148.SGD","LU0345780950.USD","LU0345768740.USD","GFI","BK4559","LU0572940350.SGD","LU0348723411.USD","LU2404859667.USD","LU0300736492.USD","LU0354030511.USD","LU2271345857.HKD","NWMX","CLDX","IE00BFXG0V08.USD","IE00BMPRXQ63.HKD","LU1366192091.USD","LU0689472784.USD","LU2756315664.SGD","LU0942090050.USD","IE00BJJMRX11.SGD","LU2242650005.HKD","LU2317271919.USD","LU0320765489.SGD","LU0878866978.SGD","LU2552382132.HKD","HMH","BK4598","LU2065171311.SGD","LU1064927863.SGD","LU2417539215.USD","BK4588","HK0000914686.HKD","IE0002270589.USD","LU0742534661.SGD","LU2471134879.HKD","LU0820561818.USD","LU1430597077.USD","LU0127658192.USD","LU0345780281.USD","LU0053671581.USD","LU2456880835.USD","LU2357305700.SGD","LU0985320562.USD","LU2602419157.SGD","IE00BJLML261.HKD","LU2063271972.USD","LU0054578231.USD","IE00B1BXHZ80.USD","FCX","IE00B3CCJ963.GBP","LU0132412106.USD","LU0868494708.USD","LU1778281490.HKD","LU1880398554.USD","LU1852331112.SGD","LU0417517546.SGD","LU2065169927.USD","LU1066053197.SGD","LU2471134523.USD","LU2430703178.SGD","LU0128525929.USD","LU0672654240.SGD","LU2362540622.SGD","LU2462611646.USD","SG9999018865.SGD","IE00B894F039.SGD","LU2498475776.HKD","LU2420271590.USD","SG9999014914.USD","LU2065731478.USD","LU0494093205.USD","LU1267930730.SGD","LU1035775433.USD","LU1992135472.HKD","LUV","LU2430703095.HKD","IE000M9KFDE8.USD","LU0719512351.SGD","IE00BJTD4N35.SGD","BK4524","BK4534","BK4566","LU1046248800.SGD","LU0708995401.HKD","LU1223082196.USD","SG9999002224.SGD","LU1119994496.HKD","BK4500","LU0648000940.SGD","LU0792757196.USD","IE000MB6IJN5.SGD","LU2505996681.GBP","HLXX","LU0690374961.EUR","LU2360106780.USD","IE0003U64NQ7.SGD","LU0654597011.USD","IE0005OL40V9.USD","LU1037948541.HKD","LU2452424414.USD","LU0251131958.USD","SG9999015358.SGD","LU1868836591.USD","LU0912757837.SGD","LU1267930227.SGD","IE00BWXC8680.SGD","LU0130102774.USD","NEM","LU2265009873.SGD","LU1868837136.USD","LU0098860793.USD","IE000ITXATA3.USD","LU0823421333.USD","SG9999014906.USD","LU2272731782.SGD","LU0957791311.USD","LU1823568750.SGD","LU1861559042.SGD","IE00BFSS7M15.SGD","LU1127390331.HKD","LU1934455863.HKD","LU1633808545.USD","LU1496350502.SGD","SG9999014575.USD","IE000WAW04H5.SGD","LU1429558221.USD","LU2860962120.EUR","SG9999015945.SGD","LU0498741114.HKD","IE000W1ABFV2.USD","GB00BDT5M118.USD","LU1582987324.SGD","LU0265550359.USD","BK4579","LU0154245756.USD","LU1868836757.USD","LU2129689431.USD","LU0264606111.USD","LU0345774391.USD","LU2361044949.HKD","AMZW","CDE","LU0256331488.USD","LU1935043536.SGD","BK4592","IE000SO60NU8.SGD","LU2168563687.JPY","LU0267386448.USD","LU0162691827.USD","LU1691799644.USD","LU1366334578.USD","LU0052756011.USD","LU1066051811.HKD","LU1116320737.USD","LU0572939691.SGD","LU0955669360.SGD","LU2242649171.HKD","LU0310799852.SGD","SG9999014559.SGD","LU1162221912.USD","LU0048573561.USD","BHP","BK4550","LU0251142724.SGD","BK4210","INO","LU0985489474.SGD","LU1244550221.USD","LU1674673428.USD","IE0001KFT4U8.USD","BK4538","SG9999017495.SGD","HL","LU0310800379.SGD","IE00B19Z8W00.USD","LU0203345920.USD","LU0238689110.USD","LU0724618789.USD","AMZZ","LU1235294995.USD","BK4213","LU2250418816.HKD","LU0011850046.USD","IE00BKDWB100.SGD","LU0154236417.USD","IE00BYQQ9H92.USD","LU2111349929.HKD","LU0345774631.USD","LU1066051498.USD","LU0971552830.HKD","LU1934455277.USD","LU2236285917.USD","LU1153585028.USD","LU0079474960.USD","LU0498741890.SGD","IE00B7KXQ091.USD","IE00BKVL7J92.USD","LU0048584097.USD","BK4543","LU1791710400.SGD","BK4583","LU1223082519.USD","LU0072462426.USD","LU2463028550.USD","LU2471134796.USD","LU0345770308.USD","SG9999002232.USD","LU2347655156.SGD","LU0276348264.USD","RIO","BK4554","LU0203201768.USD","IE000KEQY171.SGD","LU0353189680.USD","LU0107464264.USD","IE00B2Q91V27.USD","BK4179","BK4533","LU0203202063.USD","LU1074936037.SGD","LU2746668974.SGD","LU2129689514.USD","LU0345769631.USD","IE00BMPRXN33.USD","LU0210528500.USD","LU1989764748.USD","BK4127","LU1323610961.USD","AMZD","AMZN","LU0170899867.USD","AZYY","BK4548","LU0690374615.EUR","LU0210533765.USD","LU0786609619.USD","IE00B7SZLL34.SGD","SGXZ31699556.SGD","LU0345768153.USD","EL","LU0965509101.SGD","LU2237957811.SGD","LU2092627202.USD","LU2097829019.USD","LU2089284900.SGD","LU0630314457.HKD","LU1037948897.HKD","BK4570","LU1130305938.SGD","LU2077746001.SGD","LU1078025761.USD","LU2168564149.EUR","BK5111","LU0788109121.HKD","BK4516","LU1914381329.SGD","LU0266512473.USD","BK4504","LU0308772762.SGD","LU0791591158.USD","IE00BKPKM429.USD","LU1935042488.USD","LU0171293334.USD","LU2430703251.USD","SG9999014567.USD","IE00B4JS1V06.HKD","LU1732800096.USD","LU1929549753.HKD","LU1992135399.USD","BK4503","BK4568","LU1316542783.SGD","LU2168564222.USD","LU1066051225.USD","BK4551","LU0354030438.USD","LU0061474960.USD","LU0109392836.USD","LU2023250504.SGD","IE00B19Z9P08.USD","LU0528227936.USD","LU1868836914.USD","LU1868837300.USD","LU2361045086.USD","SG9999015978.USD","SG9999014542.SGD","LU0300736062.USD","LU0070302665.USD","SG9999015986.USD","LU0353189763.USD","IE00BJTD4V19.USD","BK4547","LU2083900584.USD","LU0330918003.SGD","SG9999001440.SGD","BK4585","LU2326559502.SGD","IE00BGHQF524.EUR","LU1718418525.SGD","LU2505996509.AUD","DAL","LU0203347892.USD","LU0072461881.USD","LU1201861165.SGD","LU0861579265.USD","LU1732799900.SGD","IE00B19Z3B42.SGD","BK4209","IE00BQXX3C00.GBP","IE00BZ9MQY76.HKD","IE00B3M56506.USD","LU2023250843.SGD","LU0345777659.USD","IE0004445239.USD","LU0097036916.USD","LU0158827781.USD","BK4527","LU0889565833.HKD","LU0612318385.USD","LU2756315318.SGD","IE00B775H168.HKD","LU0056508442.USD","LU0342679015.USD","BK4089","IMVT","LU0161305163.EUR","LU0795875086.SGD","LU0256863902.USD","LU0128525689.USD","LU0640476718.USD","LU0683600562.USD","BK4139","BK4507","BK4201","LU2168564495.EUR","IE00B1XK9C88.USD","LU0433182093.SGD","LU0390134368.USD","LU0310800965.SGD","LU1883866441.USD","LU1894683348.USD","FCXG","LU0061475181.USD","LU1223083913.SGD","LU2720916845.USD","LU1023059493.AUD","LU1244550577.SGD","LU0211327993.USD","LU2592432038.USD","LU0795875169.SGD","LU1804176565.USD","IE00BQXX3F31.USD","LU1988902786.USD","SG9999018857.SGD","LU0965508806.USD","SGXZ51526630.SGD","LU2764262908.HKD","LU0965509283.SGD","LU2028103732.USD","SG9999002521.SGD","LU0724617625.USD","LU1280957306.USD","LU2404859741.USD","BK4007","NEMG","LU2089283258.USD","LU2750360997.AUD","LU0265550946.USD","LU1803068979.SGD","LU0082616367.USD","LU1814569148.SGD","LU1084165304.USD","IE00BZ1G4Q59.USD","LU0251132253.USD","IE0009356076.USD","IE00BWDBJ516.SGD","LU2275660780.HKD","IE00BN29S564.USD","IE00BMPRXR70.SGD","LU2543165471.USD","LU0011963245.USD","LU0787776722.HKD","LU1582986359.USD","LU0053666078.USD","AAL","IE0000B7K699.USD","BK4561","LU0496367417.USD","LU1435385759.SGD","LU0965509010.AUD","LU2463526074.USD","LU2023250330.USD","LU0320765059.SGD","LU0823411888.USD","LU1883839398.USD","LU0234572021.USD","LU0289960550.SGD","LU2750360641.GBP","LU1861127337.USD","LU2211817866.USD","IE00BJJMRY28.SGD","IE000BZT7R73.USD","IE00BK4W5M84.HKD","LU1267930490.SGD","LU0080751232.USD","XOMO","SG9999015341.SGD","LU1720051017.SGD","LU0320765646.SGD","LU0788108826.HKD","LU2125154935.USD","BK4122","IE0034235071.USD","LU1150488218.USD","IE00B4YYXB79.USD","IE000F7OJYX1.SGD","LU0130103400.USD","USAW.SI","LU2211815571.USD","IE00B5TLWC47.USD","BK4581","LU0029864427.USD","IE00BQXX3D17.EUR","SG9999001077.SGD","DVN","LU1917777945.USD","LU2462157665.USD","SG9999014898.SGD","LU0823434583.USD","LU0158827948.USD","LU0791590937.USD","LU1302929846.USD","LU0096364046.USD","LU2461242641.AUD","LU1145028129.USD","LU1232071149.USD","LU1309081286.SGD","LU2272731600.USD","LU1839511570.USD","SGXZ23171101.USD","LU1934455194.USD","BK4532","IE00B19Z3581.USD","LU0149725797.USD","LU2362541513.USD","LU1815333072.USD","LU2133065610.SGD","LU0642271901.SGD","BK4015","LU0096362180.USD","LU0345777147.USD","LU2247934214.USD","LU0215105999.USD","LU0456854461.SGD","IE0004445015.USD","LU0316494557.USD","LU1201861249.SGD","LU1582986433.USD","IE00B3SWFQ91.USD","LU0211328371.USD","LU2213496289.HKD","LU0234570918.USD","LU1720051108.HKD","SGXZ81514606.USD","LU2237957902.USD","SGXZ99366536.SGD","LU0154245673.USD","LU0868494617.USD","LU0345769128.USD","LU1046421795.USD","LU1551013425.SGD","LU0208291251.USD","LU2381873111.SGD","LU1548497426.USD","BK4008","LU0943347566.SGD","LU0266512127.USD","LU0980610538.SGD","LU2403377893.USD","LU1116320901.HKD","LU2764263039.SGD","LU2087625088.SGD","LU1244550494.USD","BK4604","LU0882574139.USD","LU0964807845.USD","LU2108987350.USD","IE00B775SV38.USD","BK4220","AALG","CVX","LU0122376428.USD","LU0157215616.USD","LU2896262040.SGD","LU0210536198.USD","LU0505663152.USD","LU2168564065.EUR","LU0889566641.SGD","SG9999001143.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624161526","title":"BRIEF-Celldex Announces Pricing Of $300 Million Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2624161526","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624161526?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:48","pubTimestamp":1775094534,"startTime":"0","endTime":"0","summary":"BRIEF-Celldex Announces Pricing Of $300 Million Public Offering Of Common StockApril 1 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX ANNOUNCES PRICING OF $300 MILLION PUBLIC OFFERING OF COMMON S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUABMFXPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624261665","title":"Celldex Therapeutics Inc - Prices Public Offering of 10,345,000 Shares at $29.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2624261665","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624261665?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:48","pubTimestamp":1775094499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUABMFXPL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624418555","title":"BUZZ-Celldex Therapeutics drops on unveiling stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624418555","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624418555?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:23","pubTimestamp":1775075028,"startTime":"0","endTime":"0","summary":"BUZZ-Celldex Therapeutics drops on unveiling stock offering** Shares of Celldex Therapeutics CLDX.O down 5.3% at $29.60 in extended trading as it seeks equity raise** Hampton, New Jersey-based biotech firm commences stock offering; deal size not disclosed** It intends to use net offering proceeds to fund ongoing commercial readiness activities and launch of barzolvolimab, if approved, for treatment of Chronic Spontaneous Urticaria  in the U.S., fund other product candidates, grow its bispecific antibody platform, among other purposes** CSU is a condition characterized by chronic, itchy hives and swelling** Leerink Partners and TD Cowen joint bookrunners for offering** With ~66.6 mln shares outstanding, CLDX has ~$2 bln market cap** Stock closed down 1.5% at $31.26 on Weds. Still, shares up 15% YTD and ~85% over the past 12 months** Of 16 analysts, 14 rate the stock \"strong buy\" or \"buy\", 1 rates \"hold\" and 1 recommends \"sell\"; median PT $48, per LSEG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL6N40K1BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","BK4207","CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624549557","title":"Celldex commences underwritten public offering of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2624549557","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624549557?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:01","pubTimestamp":1775073719,"startTime":"0","endTime":"0","summary":"Underwriters expected to receive 30-day option to buy up to 15% more shares.Net proceeds earmarked for commercial readiness activities, including planned US launch of barzolvolimab for CSU if approved.Funds also targeted for pipeline development, including barzolvolimab programs.Leerink Partners, TD Cowen named joint bookrunning managers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6hWjrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","LU2210149790.SGD","BK4139","IE00BN0W2T93.GBP","BK4207","MNSH","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","NDAQ","BK4588","BK4585","IE00BN0W2W23.USD","IE00BKPKM429.USD","CLDX","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624495645","title":"Celldex Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2624495645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624495645?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:01","pubTimestamp":1775073660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA7GM02M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622875605","title":"BRIEF-Celldex Therapeutics Presents Positive Phase 2 Data For Barzolvolimab In CSU, ColdU, And SD","url":"https://stock-news.laohu8.com/highlight/detail?id=2622875605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622875605?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:24","pubTimestamp":1774625076,"startTime":"0","endTime":"0","summary":"BRIEF-Celldex Therapeutics Presents Positive Phase 2 Data For Barzolvolimab In CSU, ColdU, And SDMarch 27 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX THERAPEUTICS INC - PRESENTS POSITIVE PHASE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878477","title":"Celldex data shows improvements across six DLQI Domains in barzolvolimab trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622878477?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:35","pubTimestamp":1774622113,"startTime":"0","endTime":"0","summary":"Celldex (CLDX) presented additional data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria and cold urti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-data-shows-improvements-across-six-dlqi-domains-in-barzolvolimab-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-data-shows-improvements-across-six-dlqi-domains-in-barzolvolimab-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622987858","title":"Celldex Therapeutics Inc - Presents Positive Phase 2 Data for Barzolvolimab in Csu, Coldu, and Sd","url":"https://stock-news.laohu8.com/highlight/detail?id=2622987858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622987858?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:32","pubTimestamp":1774621928,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878371","title":"Celldex presents Phase 2 barzolvolimab data; CSU complete response reaches 71% at Week 52 due to sustained symptom control","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878371","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622878371?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:31","pubTimestamp":1774621899,"startTime":"0","endTime":"0","summary":"Celldex reported additional Phase 2 data for barzolvolimab in chronic spontaneous urticaria and in chronic inducible urticaria , and said the results were presented at the 2026 American Academy of Dermatology Annual Meeting.In a post hoc analysis of patients with well-controlled chronic spontaneous urticaria at Week 52, 94% had a Dermatology Life Quality Index  score of 0/1 at Week 52.At Week 76, 76% of those patients reported DLQI ≤5.In the Phase 2 cold urticaria and symptomatic dermographism study, barzolvolimab increased the rate of DLQI 0/1 at Week 20 by up to 3.1-fold in cold urticaria and 4.0-fold in symptomatic dermographism versus placebo.The company said quality-of-life improvements were observed across all six DLQI domains, with effects apparent by Week 4 in the 300 mg Q8W dosing group.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2DW5lp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","CLDX","SG9999014021.USD","NDAQ","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878067","title":"Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622878067?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:30","pubTimestamp":1774621800,"startTime":"0","endTime":"0","summary":"- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263841/24180/en/Celldex-Presents-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-and-Phase-2-Cold-Urticaria-and-Symptomatic-Dermographism-Studies-Demonstrating-Rapid-Profound-and-Durable-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","AD","BK4139","BK4132","PN","SD","BK4213","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621626710","title":"CytoDyn to launch pilot glioblastoma study of leronlimab with temozolomide or radiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2621626710","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621626710?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:31","pubTimestamp":1774355505,"startTime":"0","endTime":"0","summary":"CytoDyn reported that preclinical and translational data on leronlimab, a CCR5-targeting monoclonal antibody, were presented at the AACR Special Conference in Cancer Research: Brain Cancer.In an analysis of 154 primary glioblastoma tumors, CCR5 expression was higher than in normal brain tissue and was associated with poor prognosis.Cell-line experiments showed CCR5 inhibition with leronlimab or maraviroc had functional synergy with temozolomide, and leronlimab pretreatment increased radiation-induced cytotoxicity.CytoDyn said these findings support plans to initiate a pilot study evaluating leronlimab in glioblastoma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1wDSbC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","CYDY","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","CLDX","SG9999014021.USD","NDAQ","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621086006","title":"Celldex Therapeutics Shares Rise After Wolfe Research Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2621086006","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621086006?lang=en_us&edition=fundamental","pubTime":"2026-03-24 03:04","pubTimestamp":1774292647,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) shares rose 5.2% in Monday trading after Wolfe Research upgraded the stock to outperform from peer perform with a price target of $44.Intraday volume topped 1.04 million shares, compared with the daily average of 846,954.Price: 32.49, Change: +1.59, Percent Change: +5.15","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621836200","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621836200","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621836200?lang=en_us&edition=fundamental","pubTime":"2026-03-24 01:29","pubTimestamp":1774286997,"startTime":"0","endTime":"0","summary":"WeRide  reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.Insmed  said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.Wolfe Research upgraded Celldex Therapeutics  to outperform from peer perform.Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.Price: 31.94, Change: +1.04, Percent Change: +3.37","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0053671581.USD","LU0320765992.SGD","BK4124","BK4609","LU0889565916.HKD","WRD","00800","CLDX","BK4139","LU0109394709.USD","INSM"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.045},{"period":"1month","weight":0.1219},{"period":"3month","weight":0.3184},{"period":"6month","weight":0.2624},{"period":"1year","weight":0.8438},{"period":"ytd","weight":0.2471}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.475,"avgChangeRate":0.004594},{"month":4,"riseRate":0.5,"avgChangeRate":0.003939},{"month":5,"riseRate":0.282051,"avgChangeRate":-0.021096},{"month":6,"riseRate":0.5,"avgChangeRate":0.145989},{"month":7,"riseRate":0.425,"avgChangeRate":-0.012999},{"month":8,"riseRate":0.375,"avgChangeRate":-0.027935},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}